Results 311 to 320 of about 7,294,678 (325)

Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies

Molecular Oncology, EarlyView.
We investigated whether hypomethylating agents (HMAs) used in myeloid malignancies induce somatic retrotransposition. Our findings indicate that HMA treatment increases L1‐encoded protein expression but does not lead to detectable de novo retrotransposition events in either patient samples or cell lines.
Šárka Pavlová, Hana Svozilová, Marcela Krzyžánková, Radim Sonnek, Anastasiya Volakhava, Anastasia Smirnova, Tatiana Grigoreva, Zuzana Jašková, Hana Synáčková, Dennis Wahl, Michaela Bilčíková, Libor Červinek, Šárka Pospíšilová, Ilgar Mamedov, Karla Plevová   +14 more
wiley   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Tumor‐agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell‐free DNA fragmentomics

Molecular Oncology, EarlyView.
We evaluated circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer using DNA methylation, cell‐free DNA fragment lengths, and 5′ end motifs. Machine learning models were trained to estimate ctDNA levels from each feature and their combination.
Morten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, Satu Oltedal, Herish Garresori, Bjørnar Gilje, Saga Ekedal, Trygve Eftestøl, Jan Terje Kvaløy, Filip Janku, Oddmund Nordgård   +10 more
wiley   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Ten units intravenous oxytocin over 2-4 h is as effective as 30 units over 8-12 h in preventing postpartum hemorrhage after cesarean section: A randomized controlled trial.

Indian J Pharmacol, 2018
Cecilia M, Vijayaselvi R, Bansal R, Lakshmi L, Jose R.   +4 more
europepmc   +1 more source

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

Molecular Oncology, EarlyView.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla, Jana R. Crespo, Saioa Garcia‐Longarte, Marta Fidalgo, Sara del Palacio, Natalia Martin‐Martin, Onintza Carlevaris, Ianire Astobiza, Sonia Fernández‐Ruiz, Marc Guiu, Laura Bárcena, Isabel Mendizabal, Ana M. Aransay, Mariona Graupera, Roger R. Gomis, Arkaitz Carracedo   +15 more
wiley   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma

Molecular Oncology, EarlyView.
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf, Daniel Ehinger, Hans Brunnström, Mats Jönsson, Frida Rosengren, Marija Kotevska, Anna Karlsson, Mattias Aine, Christian Frezza, Maria Planck, Elsa Arbajian   +10 more
wiley   +1 more source